Further, it is also an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

India, with over 101 million diabetes patients and rising obesity rates, faces a critical need for effective treatment ...

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.

US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro tripeptide Read ahead ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing.

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.

The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...